Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Health-related quality of life (HRQoL) impact of lenvatinib (len) plus pembrolizumab (pembro) versus len plus placebo (pbo) as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC): Phase 3 LEAP-002 study.
Authors
Josep M Llovet
Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, IDIBAPS, Hospital Clinic Barcelona, University of Barcelona, Catalonia, Spain, Institució Catalana d’Estudis Avançats (ICREA), Barcelona, Spain;
Josep M Llovet , Masatoshi Kudo , Philippe Merle , Tim Meyer , Shukui Qin , Masafumi Ikeda , Ruocai Xu , Julien Edeline , Baek-Yeol Ryoo , Zhenggang Ren , Ann-Lii Cheng , Peter R Galle , Shuichi Kaneko , Hiromitsu Kumada , Shital Kamble , Josephine M Norquist , Kalgi Mody , Leonid Dubrovsky , Abby B. Siegel , Richard S. Finn
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Clinical Trial Registration Number
NCT03713593
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 506)
DOI
10.1200/JCO.2023.41.4_suppl.506
Abstract #
506
Poster Bd #
A16
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Lenvatinib plus pembrolizumab versus lenvatinib alone as first-line therapy for advanced hepatocellular carcinoma: Longer-term efficacy and safety results from the phase 3 LEAP-002 study.
First Author: Richard S. Finn
Poster
2022 ASCO Annual Meeting
Health-related quality of life (HRQoL) impact of pembrolizumab (pembro) plus best supportive care (BSC) versus placebo (PBO) plus BSC as second-line (2L) therapy in patients (pts) in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study.
First Author: Shukui Qin
Poster
2019 ASCO Annual Meeting
Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study.
First Author: Josep M Llovet
Poster
2022 ASCO Genitourinary Cancers Symposium
Phase 3 study of first-line treatment with pembrolizumab + belzutifan + lenvatinib or pembrolizumab/quavonlimab + lenvatinib versus pembrolizumab + lenvatinib for advanced renal cell carcinoma (RCC).
First Author: Toni K. Choueiri